
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
Workflow in the Age of AI
2
The AI Churn Trap in Life Sciences and How to Break It
3
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
4
ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism
5